fbpx

Exerpts from the publication

Background
A recent open-label pilot study (N=15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone.

Excerpt from results
At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent.

Conclusion
These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction.

Read more

Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

Steven Pennybaker, Brian J. Roach, Susanna L. Fryer, Anusha Badathala, Art W. Wallace, Daniel H. Mathalon & Tobias F. Marton
August 2021

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Dominika Psiuk, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, and Marzena Samardakiewicz
August 2021

Anti-inflammatory and analgesic actions of bufotenine through inhibiting lipid metabolism pathway

Jiaojiao Wang, Dihui Xu, Lili Shen, Jing Zhou, Xiang Lv, Hongyue Ma, Nianguang Li, Qinan Wu, Jinao Duan
August 2021

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials

Lisa Jerome, Allison A. Feduccia, Julie B. Wang, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer, Rick Doblin
June 2020

Details